Search results for #ESMO23
Expert Laurence Albiges brings us a review of the renal cell carcinoma (RCC) emerging data likely to impact clinical practice Did you miss any important updates from the #ESMO23 symposium? Find out with @AlbigesL ow.ly/y53z50QRcXT #MedEd #RCC
PHASE III ALINA Trial data was just published in @NEJM. Follow the NSCLC Key Opinion Leader Discussion of the publication, editorial by @APassaroMD and @peters_solange, as well as the KOL discussion from ALINA data presented at #ESMO23 by @bensolomon1 and the discussant…
Be sure to listen to our discussion of the first ALINA presentation by Dr. @bensolomon1 at #ESMO23 in the @IASLC podcast, Lung Cancer Considered. Drs. @NarjustFlorezMD @DrJNaidoo and I review ALINA and adjuvant #ALK targeted therapy at timestamp 26:10! iaslc.org/iaslc-news/lun…
Follow the Key Opinion Leader Sentiment of the TROPION-BREAST01 clinical trial presentations from #ESMO23 and #SABCS23 (@dradityabardia). 👉beta.kolpulse.com/public/1409290… Key Commentary from @GeorgeSledge51 @hoperugo @stolaney1 @ErikaHamilton9 @BianchiniGP @LucaVisani2 #bcsm
Follow the Key Opinion Leader Sentiment of the TROPION-BREAST01 clinical trial presentations from #ESMO23 and #SABCS23 (@dradityabardia). 👉beta.kolpulse.com/public/1409290… Key Commentary from @GeorgeSledge51 @hoperugo @stolaney1 @ErikaHamilton9 @BianchiniGP @LucaVisani2 #bcsm
@thenasheffect @SWOG @SWOGChair @SupportingSWOG @seattle @EladSharonMD @StephensonCC @VivekSubbiah @Dr_R_Kurzrock @PrimoLaraMD @DrDawnHershman @NaglaAKarimMD @SarahCannonDocs @BurrisSkip @montypal @AminNassarMD @HMAbushukair Congratulations, boss!!! Very well deserved!! Now I really regret not getting our picture together at #ESMO23! 😝
Innovative #ProstateCancer therapy insights unveiled at the #ESMO23 meeting. @AlanBryce9 @MayoClinic joins @zklaassen_md @GACancerCenter in this discussion on UroToday > bit.ly/46lTxok @myESMO
Expert Laurence Albiges brings us a review of the renal cell carcinoma (RCC) emerging data likely to impact clinical practice Need a recap of the important updates from the #ESMO23 symposium? Listen with expert @AlbigesL here ow.ly/G4MA50QRcQf #MedEd #RCC
ICYMI: ArteraAI proudly announced its research project supported by @Movember, following a study presented at #ESMO23, successfully validating the #prognostic performance of ArteraAI's MMAI in advanced #prostatecancer; funded by #Movember & @ProstateUK: bit.ly/3vs1BHz
In Annals of Oncology, the @myESMO Clinical Practice Guideline interim update on 1st-line therapy in advanced urothelial carcinoma following the results of the EV-302/KEYNOTE-A39 randomized phase 3 trial initially presented by @tompowles1 at #ESMO23 annalsofoncology.org/article/S0923-…
@KatsuakiMaehara @RenoHemonc @KE_Gallaway @JuliaRotow Not positive data is still important data! Applauding @JuliaRotow for great presentations at #ESMO23 and #DAVAVictoriaADCs (Abbvie discontinued ABBV-637 last November)
💫ONCOnews💫 🌟 ArteraAI & Movember Announce New Relationship 👉 Following the study presented at the #ESMO23 - "ArteraAI Validates its Prognostic Model in Advanced Prostate Cancer" 🔗bit.ly/3TylxBL
We are thrilled to have our research supported by @Movember! The announcement follows a study presented at #ESMO23, successfully validating the #prognostic performance of ArteraAI's MMAI model in advanced #prostatecancer; funded by #Movember & @ProstateUK: bit.ly/4aaI90U
Clinicians discuss data on the ROS1 TKI taletrectinib in patients with locally advanced or metastatic ROS1-positive non–small cell lung cancer. @jpmd901 @west_cancer #ESMO23 #lcsm onclive.com/view/taletrect…
